Being evaluated for relief of abdominal pain associated with IBS with diarrhea (IBS-D)

About MD-7246

MD-7246 is being evaluated as a potential visceral, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with IBS. We are planning to evaluate MD-7246 in a Phase II trial in patients suffering from IBS with diarrhea (IBS-D). The trial is expected to begin in 2Q 2019.

  • Compound
  • Indication
  • Approval
  • MD-7246 Partner
  • Abdominal pain associated with IBS-D

  • Phase II trial results targeted mid-2020

Represents ongoing phase of development; does not correspond to completion of a particular phase.

About IBS-D

Approximately 16 million patients suffer from IBS-D in the United States. These patients report frequent abdominal pain (approximately 86 days of the year), discomfort and bloating, along with stools that are more loose or frequent than usual. More than 80% of surveyed patients report IBS-D symptoms as somewhat to extremely severe.

How MD-7246 is Thought to Work

MD-7246 is designed to release linaclotide in the distal ileum near the ileocecal junction. Because of this, it has the potential for strong abdominal pain relief with limited impact on bowel effects.

MD-7246 Clinical Trials

A randomized, double-blind, placebo-controlled Phase II trial of MD-7246 is planned. This trial is designed to evaluate the safety, tolerability and treatment effect on abdominal pain of MD-7246 in IBS-D patients.

Copyright © 2020, Ironwood Pharmaceuticals, Inc. All Rights Reserved

LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.